Answers are grounded in this paper and cite their sources.
Social Hygiene Service, Department of Health, Hong Kong SAR; and 1Department of Ophthalmology and Visual Sciences, Prince of Wales Hospital, Shatin, Hong Kong, People's Republic of China Sir, Dr Ferreira and colleagues [1] have given an excellent description of a lupus patient with Devic's syndrome (neuromyelitis optica, NMO) but it seems that a fundamental issue of this case has not been answered. Was this patient suffering from NMO with inflammatory demyelinating disease targeting the optic nerves and spinal cord as described, or a genuine case of multiple sclerosis (MS) instead? It is of paramount importance to make a clear distinction between these two entities; this is of interest not only academically but also because of the markedly disparate clinical outcomes and therapeutic strategies [2–4]. In the largest retrospective comparative study of 30 NMO and 50 MS patients, it has been shown that NMO usually carries a much graver prognosis [2]. Furthermore, NMO and MS differ substantially in treatment, as the immunomodulatory drugs typically used for MS will be ineffective for relapse prevention in NMO and severe refractory attacks in NMO usually necessitate rescue plasmapheresis or more effective immunosuppressive therapies [3].
No takes yet. Share an insight, caveat, or question.
Chan et al. (2005) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: